OncoMatch/Clinical Trials/NCT07477912
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Is NCT07477912 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies anti BCMA CAR-T cells for multiple myeloma refractory.
Treatment: anti BCMA CAR-T cells — The mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
resistance to proteosome inhibitors
Must have received: immunomodulator
resistance to ... immunomodulators
Cannot have received: anti-BCMA therapy
Prior anti BCMA therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0 × 10^9/L; Absolute lymphocyte count ≥0.3 × 10^9/L (at enrolment and prior to leukapheresis); Haemoglobin ≥80 g/L; Platelets ≥50 × 10^9/L
Kidney function
Creatinine clearance ≥30 cc/min
Liver function
Serum alanine aminotransferase / aspartate aminotransferase ≤2.5 x ULN; Total bilirubin ≤1.5 x ULN, except in subjects with Gilbert's syndrome
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50% (by echocardiogram [ECHO])
Adequate organ system function including - Creatinine clearance ≥30 cc/min. - Serum alanine aminotransferase / aspartate aminotransferase ≤2.5 x upper limit of normal (ULN). - Total bilirubin ≤1.5 x ULN, except in subjects with Gilbert's syndrome. - Left ventricular ejection fraction (LVEF) ≥50% (by echocardiogram [ECHO]) - Baseline oxygen saturation >92% on room air and ≤Grade 1 dyspnoea. Adequate bone marrow (BM) function * Absolute neutrophil count ≥1.0 × 10^9/L. * Absolute lymphocyte count ≥0.3 × 10^9/L (at enrolment and prior to leukapheresis). * Haemoglobin ≥80 g/L. * Platelets ≥50 × 10^9/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify